A study of infant bronchiolitis-coded episodes described the proportion of events attributable to respiratory syncytial virus (RSV) and demonstrated that episodes occurring during the peak months of winter viral season, among younger infants, and among those with higher levels of care, were more likely to be attributable to RSV. Researchers using ICD-coded data to describe health-care utilization due to respiratory viral disease face a difficult challenge: ICD codes cannot tell them precisely which events are due to a specific virus. Although virus-specific codes are available for the most common viral pathogens, and those codes are utilized by providers, patients with those codes may or may not have had laboratory testing to confirm the presence of the specific virus. Additionally, providers can use "unspecified" codes even if laboratory testing was conducted and a pathogen was identified. As a result, researchers must interpret virus-specific codes that may not be accurate and that underrepresent the true incidence of disease along with unspecified codes that have decreased and unknown specificity for the disease. This problem is particularly acute within RSV research given current recommendations against routine laboratory testing for RSV. to be due to RSV with testing, 25% to 35% had an RSV-specific ICD code and 65% to 79% had a bronchiolitis ICD code. 3 Similarly,
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